Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
about
The pathophysiology of thrombocytopenia in chronic liver diseaseThe prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balanceAdvances in the development of thrombin inhibitorsA novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary cultureTissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in ratsCollagen-like proteins of pathogenic streptococciDrotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.Molecular recognition mechanisms of thrombin.Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N.Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsisFibrinolysis is amplified by converting alpha-antiplasmin from a plasmin inhibitor to a substrate.Molecular intercommunication between the complement and coagulation systemsThrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis.Thrombomodulin.Hypercoagulable states and strokes.Fibrinolysis, inflammation, and regulation of the plasminogen activating system.Role of adipose tissue in haemostasis, coagulation and fibrinolysis.The effect of cigarette smoke extract on thrombomodulin-thrombin binding: an atomic force microscopy study.Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity.Recent advances in hemophilia B therapy.Overview of Blood Coagulation.A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).Downregulation of Clock in circulatory system leads to an enhancement of fibrinolysis in mice.Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis.Isolation, Co-Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa)Thrombin activatable fibrinolysis inhibitor as a bleeding predictor in liver transplantation: a pilot observational study.Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease.Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica.In situ assays demonstrate that interferon-gamma suppresses infection-stimulated hepatic fibrin deposition by promoting fibrinolysis.Thrombin inhibitory activity of some polyphenolic compounds.The unfolding pathway of leech carboxypeptidase inhibitor.Elevated plasma protein C levels correlate with the presence of fatty liver (NASH and NAFLD).Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency.The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis.Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?
P2860
Q26749277-1B99EA51-5E98-433F-885D-CF58BD930F7CQ27003277-AA45C828-13F4-4A68-9DE9-8051C85DE6C2Q28182480-0BE4E020-1B5C-4EC8-B330-74157329F9F4Q28571160-4A09F530-0744-452A-B055-06DD78B00DF8Q28573067-C49AF7BB-ED9E-4FBC-AC2C-9C4909530F81Q29248479-440568AF-2667-4B38-80E7-D07EF6388D65Q30788622-0C6F8140-A563-4D12-99B1-94B5CD71BF7AQ33221756-763AE341-1DE5-42E0-84B7-2F48E1C3D1AAQ34122609-E3F132BC-0DAD-4999-A01F-342571439BEEQ34469113-3678F868-34A6-4608-BE7B-CD29197904AEQ34691371-872AB912-062F-4D1A-83D6-FF1122A4BEE0Q35067949-7336BB3F-46D2-4452-B588-4E41FF0DA7D7Q35088199-348A988F-7021-4F38-9CA4-3776CAACFB86Q35181628-A3321B04-2A6A-4C40-AAF2-32FD19961854Q36527933-6AC31649-83F3-48C7-9809-A4165B94CB29Q36884356-A4018422-4EB7-4E60-B5C9-7D1199AD4CF2Q37491351-9BA293BC-F6C8-4CF3-95A9-109FEF895458Q38320390-2123DAB9-904A-442C-BD0E-DA472E458BE5Q38353746-685C8DBB-785F-4F71-889F-7B17AA9134D7Q39154043-3843AB3F-76E5-4418-8545-3574C33E98E3Q39269270-36093B2E-41C3-48FE-82C5-5A87A97D121EQ39392420-23867F9E-D4BE-48DB-A249-7A8EFA6D7AC6Q39508094-E91F7D86-6789-415E-8F76-6C6C01A6432FQ39736724-E557652B-0FFD-43DB-9D73-2D7C0EFA75FEQ40548565-2F659D7E-C1D3-45CF-AE50-7D521ADA99B5Q40653968-8616038E-154C-4F25-BD08-6414576152EEQ40666861-1EB57542-DFA1-48D1-B69A-F055EC063EBDQ41428336-370F7EFD-F0EB-4F3C-9E7A-5FC65AC67D72Q41474057-BE203E3B-E117-42D7-9A7A-8DCD8D782829Q41987745-6993F27C-E58E-4C25-9070-DA32DBE1DAD6Q42672161-3FABB7A3-04D5-47EA-80D0-23C7F70EAC01Q43004440-4A108298-AE0E-4DAD-A9B4-82B6AD4A1C90Q43188577-B1399A51-23FF-4DC5-9091-2843CE472B69Q43230368-D5AAC213-4082-4994-97B8-3C0D58448A9BQ44311743-D41F78C3-3F73-4974-82BD-1354D961DC1AQ45208151-EAA62193-4E9A-47A8-BEE4-27C0A4771B39Q45859203-2B5E46E3-5524-4337-A9B7-0B7DE571C160Q45880180-57D64D24-D89F-41B3-AAD6-200441C5E8C3Q45885169-98FC8B75-35A9-43FC-A79F-9E8B3ADEF87BQ46134025-40F97827-3E9D-4673-AAFF-92982312D8F2
P2860
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
@ast
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
@en
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
@nl
type
label
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
@ast
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
@en
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
@nl
prefLabel
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
@ast
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
@en
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
@nl
P1476
Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
@en
P2093
P304
P356
10.1161/01.ATV.20.12.2511
P407
P577
2000-12-01T00:00:00Z